Active	Status	Sponsor type	Region	Phase	Filter
2 Active 9 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ziresovir (AK0529) / Ark Biosci
AK0529-2007, NCT06775405: A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants	Recruiting	3	180	RoW	AK0529, Placebo	Shanghai Ark Biopharmaceutical Co., Ltd.	Respiratory Synctial Virus Infections	08/25	09/25
NCT06591845: Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects	Not yet recruiting	1	32	NA	Ziresovir 125 mg, Ziresovir 500 mg, Placebo, Moxifloxacin hydrochloride tablet 400 mg	Shanghai Ark Biopharmaceutical Co., Ltd.	Healthy Volunteers	12/24	12/24